argenex SE (ARGX) vs Genmab A/S Sponsored ADR (GMAB)

argenex SE and Genmab A/S Sponsored ADR are both Biotechnology companies. argenex SE is the larger, with a market value of $56.3B against $31.5B — 1.8× the size. argenex SE trades at the lower P/E: 29.8× against 41.7×. argenex SE grew revenue faster over the last twelve months: 60.8% against 22.3%. argenex SE has the higher net margin (31.7% vs 19.1%) and the lower return on invested capital (0.00% vs 6.99%). Across the 21 metrics below, argenex SE leads on 13 and Genmab A/S Sponsored ADR on 8.

Valuation

Metric ARGX GMAB Biotechnology median
P/E 29.82 41.72 10.26
P/S 9.52 7.87 9.18
P/B 6.71 5.46 2.05
Price to free cash flow 40.96 n/m 24.81
EV/EBITDA 30.39 30.99 0.65
EV/Sales 8.92 8.75 8.98
Earnings yield 3.35% 2.40% (34.89%)
Free cash flow yield 2.44% (19.53%) (24.52%)

Profitability

Metric ARGX GMAB Biotechnology median
Gross margin 90.21% 93.03% 65.16%
Operating margin 29.34% 25.95% 0.00%
Net margin 31.68% 19.08% 0.00%
Free cash flow margin 0.00% (153.64%) 0.00%
Return on equity 0.00% 14.00% (50.12%)
Return on assets 0.00% 8.30% (45.60%)
Return on invested capital 0.00% 6.99% 0.00%

Growth

Metric ARGX GMAB Biotechnology median
Revenue growth (TTM) 60.84% 22.26% 6.26%
EPS growth (last fiscal year) 53.13% (12.50%) 29.88%
Revenue growth, 5-year CAGR 130.77% 19.15% 9.75%
Net income growth, 5-year CAGR 0.00% 5.73% 0.00%

Health

Metric ARGX GMAB Biotechnology median
Debt to equity 0.00 0.86 0.00
Current ratio 5.12 2.46 4.89
Net debt to EBITDA (3.23) 3.13 1.01

Dividend

Metric ARGX GMAB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ARGX GMAB Biotechnology median
Market cap 56.27b 31.51b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack